News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Release: One- & Two-Year Survival Rates of 94% And 88% Announced From Phase 1b Trial Of Investigational PD-1 Checkpoint Inhibitor Nivolumab And Yervoy® (ipilimumab) In Advanced Melanoma; Ongoing Phase 2/3 Trials To Confirm Results



6/2/2014 8:52:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab, an investigational PD-1 immune checkpoint inhibitor, and Yervoy® (ipilimumab) given either concurrently or sequentially in patients with advanced melanoma (n=127). After an additional year of follow up of the cohort that received the concurrent combination regimen of nivolumab 1 mg/kg plus Yervoy 3mg/kg (n=17), the one-year overall survival (OS) rate was 94% and the two-year OS rate was 88%.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES